VYNE Therapeutics Inc. (VYNE)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. David T. Domzalski | CEO, President & Director | 1.61M | -- | 1967 |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 856.82k | -- | 1973 |
| Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 817.97k | -- | 1975 |
| Mr. Tyler Zeronda | CFO & Treasurer | -- | -- | 1987 |
| Dr. Subhashis Banerjee M.D. | Senior Vice President of Clinical Development | -- | -- | -- |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant | 40.2k | -- | 1951 |
VYNE Therapeutics Inc.
- Sector:?
- Healthcare
- Industry:? Biotechnology
- Full Time Employees:?
- 10
Description
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Corporate Governance
Upcoming Events
November 11, 2024 at 1:30 PM UTC - November 15, 2024 at 1:30 PM UTC
VYNE Therapeutics Inc. Earnings Date
Recent Events
March 12, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
November 20, 2023 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission